Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY:NVS)

123.29 +0.68 (+0.55%)
Streaming Delayed Price Updated: 9:58 AM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
51 52 Next >
Amazon, Alphabet, Meta, Intel Q3 Earnings This Week: Will Mega-Caps Shatter Forecasts And Revive Market?
Factset data indicates that out of the 17% of the S&P 500 companies that have reported so far, 73% have reported positive EPS surprises. 
Via Benzinga
Topics Stocks
7 Healthcare Stocks to invest in for a Healthy Future
Considering today's economic uncertainty and market turns, healthcare stocks may be one of the few winning sectors. Here are the winners. 
Via InvestorPlace
2 Biotech Stocks That Could Make You Richer
These two well-known drugmakers still have some growth fuel in their seemingly empty tanks. 
Via The Motley Fool
3 Unstoppable Stocks to Buy and Hold for Decades
These stocks can be pillars for your long-term portfolio, and investing in all three offers excellent diversification. 
Via The Motley Fool
Why Top 1% Biotech MoonLake Just Surged Within Striking Distance Of A Breakout
MoonLake says it's skin-disease treatment showed improved promise in a 24-week testing update. 
Via Investor's Business Daily
Weight Loss Drugs Market Size, Share, Growth, Trends, Analysis 2028
Get an extensive Weight Loss Drugs Market analysis of the dominant vendors, their latest products and services, and the competitive landscape of the industry. 
Via SBWire
Antiparasitic Drugs Market to See Major Growth by 2023-2030 : Arbor Pharmaceuticals, GlaxoSmithKline, Cipla
Get an extensive Antiparasitic Drugs Market analysis of the dominant vendors, their latest products and services, and the competitive landscape of the industry. 
Via SBWire
RayzeBio Is A New Contender in Radiopharmaceutical Arena, Will Attract Prominent Entities: JP Morgan
JP Morgan has initiated coverage on RayzeBio Inc (NASDAQ: RYZB), representing a pure-play opportunity in the radiopharmaceutical space. 
Via Benzinga
Cancer Immunotherapies Market Set for More Growth : American Cancer Society, WebMD, Eli Lily and Company
Get an extensive Cancer Immunotherapies Market analysis of the dominant vendors, their latest products and services, and the competitive landscape of the industry. 
Via SBWire
AbbVie Stock Moves Higher With Rising Relative Strength
A Relative Strength Rating upgrade for AbbVie shows improving technical performance. Will it continue? 
Via Investor's Business Daily
Elsevier Launches New Pharmapendium, Empowering Pharma Companies to Bring Novel Drugs to Market Faster and Increase Success of Regulatory Submissions
London, United Kingdom--(Newsfile Corp. - October 10, 2023) - Elsevier, a global leader in information and data analytics, has launched... 
Via Newsfile
Topics Animal Testing
3 Artificial Intelligence Stocks That Could Outperform the ‘Godfather of AI’
These are the AI stocks to buy and hold for multibagger returns in the next 24 months, as they represent quality growth companies. 
Via InvestorPlace
Topics Artificial Intelligence
Eli Lilly, McKesson, Novartis Flash Promising Chart Action
Eli Lilly, McKesson, and Novartis are catching investors' attention with promising chart patterns and revenue growth, signaling potential buying opportunities. 
Via MarketBeat
Protecting Cannabis Products & More: New Sustainable Child-Resistant Packaging By Dymapak
Dymapak, a global manufacturer specializing in innovative child-resistant packaging solutions for various industries, has introduced a child-resistant Consumer Packaged Goods (CPG) packaging... 
Via Benzinga
Topics Cannabis
Why Cal-Maine Foods Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Gaucho Group Holdings, Inc. (NASDAQ: VINO) jumped 95.2% to $3.7280. Gaucho Group is planning to list two of its retail properties in Argentina, in San Rafael and Cordoba, for sale, priced at $2... 
Via Benzinga
Novartis Shares Decline As Spin Off Sandoz's Market Debut Falls Short of Expected Valuation
Sandoz Group AG (OTC: SDZNY) (OTC: SDZXF) enters a new era as a standalone player in generic and biosimilar medicines. 
Via Benzinga
SDZNY Stock: 7 Things to Know as Novartis Spinoff Sandoz Starts Trading Today
Sandoz (SDZNY) stock is a hot topic among traders on Wednesday as the company starts trading after a spinoff from Novartis. 
Via InvestorPlace
Cancer Drug Maker 3D Medicines Inc. Trading Higher After Company Announces It Will Repurchase Up To 10% Of Outstanding Shares
3D Medicines Inc. was trading 7.2% higher in the Hong Kong Wednesday morning session at HK$5.53 after the company announced that it is buying back up to 10% of its own stock. 
Via Benzinga
Cal-Maine Foods, A10 Networks And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures traded mixed this morning on Wednesday. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
Novartis Mulls Divesting Some Assets Of Radiopharma Unit In Strategic Shift
Swiss pharmaceutical giant Novartis AG (NYSE: NVS) is reportedly contemplating selling sections of radiopharmaceuticals company Advanced Accelerator Applications to align with the company's strategy... 
Via Benzinga
Drugmakers Agree To Participate For Medicare Drug Price Negotiation With Biden Administration
All ten manufacturers of the first drugs selected for Medicare price negotiations will be participating, the White House said, even though many of them are suing the administration  
Via Benzinga
Novartis' Investigational Therapy Shows Promising Action In Rare Kidney Disease
Novartis AG (NYSE: NVS) announced topline results from the pre-specified interim analysis of the Phase 3 APPLAUSE-IgAN study at nine months of iptacopan, an investigational factor B inhibitor targeting... 
Via Benzinga
Cardiol Therapeutics 76% YTD Gain Is A Bullish Signal Ahead Of Expected Phase III Trial Announcements ($CRDL)
Via AB Newswire
Topics Death
Fusion Pharmaceuticals Poised For Leadership In Targeted Cancer Therapies: Oppenheimer
Oppenheimer initiated coverage on Fusion Pharmaceuticals Inc (NASDAQ: FUSN), citing the company's pipeline as among the best in the space with alpha-emitter-based targeted radionuclide therapies... 
Via Benzinga
Allakos' Antibodies For Chronic Skin Conditions, Analyst Sees Over 400% Stock Upside
JMP Securities initiated coverage on Allakos Inc (NASDAQ: ALLK), noting novel monoclonal antibodies targeting Siglec (sialic acid immunoglobulin-like lectin) receptors on immune cells that are drivers... 
Via Benzinga
Ionis-Roche Join Forces To Compete In Neurodegenerative Disease Space, Analyst Sees Short-Term Challenges
Ionis Pharmaceuticals Inc (NASDAQ: IONS) entered an agreement with Roche Holdings AG (OTC: RHHBY 
Via Benzinga
Health Insurer Centene Streamlines - Plans Massive Layoffs To Cut Costs: Report
Centene Corporation (NYSE: CNC) is reportedly laying off about 3% of its workforce as the health insurer plans to cut expenditures and accelerate profits over the years. 
Via Benzinga
Topics Workforce
Benzinga's Top Ratings Upgrades, Downgrades For September 25, 2023
 
Via Benzinga
Amazon Invests $4B In ChatGPT Competitor, Hollywood Writers Accept Tentative Deal, ChatGPT Challenges Siri And Alexa With Introduction Of Verbal Responses: Today's Top Stories
Benzinga 
Via Benzinga
Novartis Sandoz Prepares For Public Debut With Strong Sales Record And Plans for New Biologic Drugs
Novartis AG (NYSE: NVS) confirmed its plans for a 100% spin-off of the Sandoz business on October 4 after shareholders approved it  
Via Benzinga
< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
51 52 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.